Marina Biotech up Thinly traded nano cap Marina Biotech (MRNA +10.6%) perks up after the company announced

Marina Biotech up 11% on SMARTICLES license deal

Marina Biotech up 11% on SMARTICLES license deal

Marina Biotech up Thinly traded nano cap Marina Biotech (MRNA +10.6%) perks up after the company announced

INVESTORS Marina Biotech up Thinly traded nano cap Marina Biotech (MRNA+10.6%) perks up after the company announced that it has out-licensed its SMARTICLES platform for the delivery of antisense DNA therapeutics to Oncotelic, a first for the company.




 

 

Marina Biotech up

 

Under the terms of the deal, Oncotelic will invest $250K in Marina via the purchase of common stock at $0.51/share. Subject to conditions, Marina may receive a commercial license fee via the sale of $500K of common shares to Oncotelic, in addition to sales-based milestones. Total potential sales milestones are capped at $90M. Additional financial terms are not disclosed.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



 Amazon buying Whole Foods  Amazon and Whole Foods Market, Inc. (NASDAQ:WFM) today announced that they have entered into a definitive merger agreement

Amazon buying Whole Foods in $14 billion deal

Amazon buying Whole Foods in $14 billion deal

 

BUZ INVESTORS  PRESS RELEASE  Amazon buying Whole Foods  Amazon and Whole Foods Market, Inc. (NASDAQ:WFM) today announced that they have entered into a definitive merger agreement under which Amazon will acquire Whole Foods Market for $42 per share in an all-cash transaction valued at approximately $13.7 billion, including Whole Foods Market’s net debt.

“Millions of people love Whole Foods Market because they offer the best natural and organic foods, and they make it fun to eat healthy,” said Jeff Bezos, Amazon founder and CEO. “Whole Foods Market has been satisfying, delighting and nourishing customers for nearly four decades – they’re doing an amazing job and we want that to continue.”

“This partnership presents an opportunity to maximize value for Whole Foods Market’s shareholders, while at the same time extending our mission and bringing the highest quality, experience, convenience and innovation to our customers,” said John Mackey, Whole Foods Market co-founder and CEO.




Amazon buying Whole Foods

Whole Foods Market will continue to operate stores under the Whole Foods Market brand and source from trusted vendors and partners around the world. John Mackey will remain as CEO of Whole Foods Market and Whole Foods Market’s headquarters will stay in Austin, Texas.

Completion of the transaction is subject to approval by Whole Foods Market’s shareholders, regulatory approvals and other customary closing conditions. The parties expect to close the transaction during the second half of 2017.

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit www.amazon.com/about and follow @AmazonNews.

Like up on FACEBOOK


logo

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD Closes $25,008,750 Bought Deal Private Placement

Invictus MD Closes $25,008,750 Bought Deal Private Placement

Private Placement

BUZ INVESTORS PRESS RELEASE Private Placement   INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS) i

BUZ INVESTORS PRESS RELEASE Private Placement   INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has closed its previously announced bought deal private placement (the “Offering”), with Canaccord Genuity Corp., Eventus Capital Corp., Echelon Wealth Partners Inc., GMP Securities L.P. and PI Financial Corp. (collectively, the “Underwriters”), including the over-allotment option, for aggregate gross proceeds of $25,008,750. A total of 18,525,000 units (the “Units”), including those pursuant to the exercise of the over-allotment option, were issued at a price of $1.35 per Unit.

Each Unit is comprised of one common share and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share (a “Warrant Share”) until November 24, 2018 at an exercise price of $1.75 per Warrant Share.

Net proceeds from the Offering will be used for expansion plans for the Company’s assets and for general working capital purposes. As compensation, the Underwriters received a commission of 5% of the gross proceeds and a corporate finance fee of 5% of the gross proceeds.



Private Placement  


All securities issued or issuable under the Offering are subject to a four-month hold period expiring on September 25, 2017.

The Company also announces the issuance of 1,000,000 common shares to an arm’s length consultant as payment for certain consulting services, including the introduction and integration of the Company’s recent acquisitions.

The Company also announces the resignation of Mike Blady from the Board.  The Company wishes to thank Mike Blady for his valuable contribution to the Company and wish him well for the future.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including investment in the fully licensed facilities operated by AB Laboratories Inc. and Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Buz Investors Oil Price Pushes UK Inflation The commodity is trading at $53.32 per barrel at 10:40 GMT this morning, 0.85% higher from the New York close.

OPEC might just let the deal on oil output cuts collapse

Chart | Calendar   | TRADE NOW | CRUDE OIL

OPEC might just let the deal on oil output cuts collapse

BUZ INVESTORS oil output cuts collapse The commodity is trading at $47.73 per barrel at 09:40 GMT this morning, 0.08% lower from the New York close.

Oil

BUZ INVESTORS   oil output cuts collapse The commodity is trading at $47.73 per barrel at 09:40 GMT this morning, 0.08% lower from the New York close. Crude oil witnessed a high of $48.07 per barrel and a low of $47.62 per barrel during the session. In the New York session yesterday, crude oil fell 0.44% to close at $47.77 per barrel, surrendering its previous session gains. Immediate downside, the first support level is seen at $47.44 per barrel, while on the upside, the first resistance level is at $48.12 per barrel.



oil output cuts collapse

>>>TRADE NOW<<<

Crude oil  | Data | Chart | Calendar | Forecast | News

Crude Oil increased 0.04 USD/BBL or 0.08% to 47.77 on Friday May 12 from 47.83 in the previous trading session. Historically, Crude oil reached an all time high of 145.31 in July of 2008 and a record low of 1.17 in February of 1946.

Crude oil is the world’s most actively traded commodity. Crude Oil prices displayed in Trading Economics are based on over-the-counter (OTC) and contract for difference (CFD) financial instruments. Our market prices are intended to provide you with a reference only, rather than as a basis for making trading decisions. Trading Economics does not verify any data and disclaims any obligation to do so. This page provides – Crude oil – actual values, historical data, forecast, chart, statistics, economic calendar and news. Crude oil – actual data, historical chart and calendar of releases – was last updated on May of 2017.

 

Actual Previous Highest Lowest Dates Unit Frequency
47.77 47.82 145.31 1.17 1946 – 2017 USD/BBL Daily

 

Energy Price Day Weekly Monthly Yearly Date
Crude Oil 47.7639 0.03 0.06 % 3.37% -10.16% 3.39% 07:57

Like up on FACEBOOK

logo


Market quotes are powered by
TradingView.com


Commodities ( Gold ) ( Silver ) ( Lithium )




BUZ INVESTORS PRESS RELEASE VNNYF to Acquire Cannabis Biopharma It’s a Done Deal! Just as we had suspected, Vinergy Resources

It’s A Done Deal! VNNYF to Acquire Cannabis Biopharma Tech Company! What Does This Mean?

|Chart | Calendar   | TRADE NOW | VNNYF

It’s A Done Deal! VNNYF to Acquire Cannabis Biopharma Tech Company! What Does This Mean?

BUZ INVESTORS PRESS RELEASE VNNYF to Acquire Cannabis Biopharma It’s a Done Deal! Just as we had suspected, Vinergy Resources

BUZ INVESTORS PRESS RELEASE  VNNYF to Acquire Cannabis Biopharma  It’s a Done Deal! Just as we had suspected, Vinergy Resources (VNNYF) today announced the signing of a definitive agreement to acquire 100% of MJ Biopharma, a cannabis technology company. We have been speculating for over a week that the halt of trading on the Canadian exchange for symbol VIN.CN was to allow for this completed acquisition, and we were right. The stock has gained as much as 36% since we re-initiated coverage on VNNYF last week in anticipation of this deal closing. But now the real fun begins…

This is a major milestone for VNNYF and its shareholders that gives a true fundamental boost to the company. The investment community has been waiting for closure on this item for some time now dating back months ago when the company first mentioned its plans for the acquisition. Back then Vinergy’s stock skyrocketed on the possibility of the deal closing but soon pulled back as investors perhaps grew tired of waiting for a definitive deal, or maybe they doubted the whole deal altogether.

Well, now today’s news from VNNYF of a signed definitive agreement will put all that uncertainty and impatience to rest while sparking a new level of interest and excitement.



VNNYF to Acquire Cannabis Biopharma

>>>TRADE NOW<<<

Incentivized Compensation Plan

Perhaps the most exciting piece of this acquisition is the means in which Vinergy is acquiring MJ Biopharma. 4.25M shares of common stock priced at $0.20CAD are to be issued upfront, 2/3 of which will be held in escrow. But MJ Biopharma management and shareholders have the opportunity to earn an additional 5M shares is they bring each of their 4 product segments to commercialization. This is a genius move by VNNYF management that could drastically increase shareholder value down the road.

What is VNNYF Acquiring?

MJ Biopharma is a cannabis technology company with a team of experienced business and medical professionals, biochemists and researchers. The company is currently focused on the following areas of interest:

  • manufacturing breath strips;
  • time release capsules;
  • extract oils;
  • food products and infused juices, teas, coffee and extract drinks;
  • pharmaceutical grade delivery systems;

 

MJ Biopharma’s expertise lies in its extracts and custom formulations. The company will also aim to inlicense and joint venture on best in class technologies and products for both the medicinal and recreational markets – domestically and internationally.

 

The Big Picture is Starting to Come Together

The company said their novel approach for its breath strip technology may become the basis for new products where water or saliva is the catalyst to activate the carrier for delivery and absorption of CBD into the body. Management believes this breakthrough could form the basis of a new technology and has the potential to create an entirely new product category. The technology is called BURST, named for the speed at which it enhances the body’s absorption of various ingredients.

And let’s not forget that VNNYF signed a binding letter of intent to acquire 65% of Biolennia Laboratories. Biolennia Labs is a specialty development laboratory with expertise in microbiology and chemistry. The lab operates out of a secure facility in Toronto alongside Micrylium, which manufactures products registered under license from several agencies. It currently provides testing, R&D, and quality control for Health Canada registered and approved industrial disinfectants and other consumer products on behalf of Micrylium.

Vinergy also reported the development of a disruptive solvent-based extraction system. The project is already underway and the company will be providing updates and more information soon. Positive results from this project could be another strong catalyst for VNNYF. And with the acquisition of MJ Biopharma finally completed, all the pieces appear to be falling perfectly into place.

What was once speculation and hype that ignited nearly a 200% move in Vinergy’s stock months ago when this acquisition was just a “possibility” has just officially become reality. The structure of this deal and the current market conditions could present great opportunity for VNNYF shareholders. So far we have seen VNNYF gain as much as 36% since we re-initiated coverage on the company but with this acquisition finally in the books, this could be just the beginning.

Pursuant to an agreement between MAPH and Vinergy Resources, we were hired for a period of 1 month from 5/1/2017 – 6/1/2017 to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD announces $20,000,000 Bought Deal Private Placement of Units

Invictus MD announces $20,000,000 Bought Deal Private Placement of Units

 

 

BUZINVESTORS PRESS RELEASE Invictus MD announces INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS) announces it has determined not to proceed

BUZINVESTORS PRESS RELEASE Invictus MD announces   INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) announces it has determined not to proceed with its previously announced offering of convertible debentures as set forth in a news release dated April 20, 2017 and instead will proceed with an offering of units with the same underwriting syndicate.  Canaccord Genuity Corp. and Eventus Capital Corp., as co-lead underwriters and joint-bookrunners, on behalf of a syndicate of underwriters (collectively, the “Underwriters“), have agreed to purchase, on a bought deal private placement basis, subject to adjustment pursuant to the Underwriters’ Option (as hereinafter defined), 14,820,000 units of the Company (the “Units“), at a price of $1.35 per Unit (the “Offering Price“) for aggregate gross proceeds of $20 million (the “Offering“). Invictus MD’s board of directors determined that completing an equity financing on the terms of the Offering aligns better with the Company’s strategic objectives than the previously announced convertible debenture financing.

Invictus MD has also granted the Underwriters an option (the “Underwriters’ Option“) to purchase up to an additional 3,705,000 Units at the Offering Price, exercisable in whole or in part at any time for a period of 48 hours prior to the closing of the Offering. If the Underwriters’ Option is exercised in full, the aggregate gross proceeds of the Offering will be $25 million.



Invictus MD announces  

>>>TRADE NOW<<<

Each Unit will be comprised of one common share of the Company and one half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one common share (a “Warrant Share”) for a period of 18 months following the closing date of the Offering at an exercise price of $1.75 per Warrant Share. Net proceeds from the Offering will be used for expansion plans for the Company’s assets and for general working capital purposes.

All securities issued or issuable under the Offering will be subject to a statutory hold period lasting four months and one day following the closing date.

Closing of the Offering is expected to occur on or about May 24, 2017 (the “Closing Date“). The Offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange.

“The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.”

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR located in both Alberta and Ontario, including Acreage Pharms Ltd. and AB Laboratories Inc. and Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Executive Chairman

Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676

Cautionary Note Regarding Forward-Looking Statements: Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “Forward-Looking Information”) within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward Looking Information includes, but is not limited to, disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action; and the plans for completion of the Offering, expected use of proceeds and business objectives. In certain cases, Forward-Looking Information can be identified by the use of words and phrases such as “anticipates”, “expects”, “understanding”, “has agreed to” or variations of such words and phrases or statements that certain actions, events or results “would”, “occur” or “be achieved”. Although Invictus has attempted to identify important factors that could affect Invictus and may cause actual actions, events or results to differ materially from those described in Forward-Looking Information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended, including, without limitation, the risks and uncertainties related to the Offering not being completed in the event that the conditions precedent thereto are not satisfied. In making the forward-looking statements in this news release, Invictus has applied several material assumptions, including the assumptions that (1) the conditions precedent to completion of the Offering will be fulfilled so as to permit the Offering to be completed on or about June 1, 2017; (2) all necessary approvals will be obtained in a timely manner and on acceptable terms; and (3) general business and economic conditions will not change in a materially adverse manner. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information. Except as required by law, Invictus does not assume any obligation to release publicly any revisions to Forward-Looking Information contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Invictus MD Strategies Corp.

Click here to visit the Invictus MD Strategies Corp. website

Like up on FACEBOOK


Ebates Coupons and Cash Back

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD announces $40,000,000 Bought Deal Private Placement of Convertible Debentures and notice of intention to exercise option on Acreage Pharms

Invictus MD announces $40,000,000 Bought Deal Private Placement of Convertible Debentures and notice of intention to exercise option on Acreage Pharms

 

BUZ INVESTORS Invictus MD announces $40,000,000 Bought Deal INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS) announced today that it has engaged Canaccord Genuity Corp. and Eventus Capital Corp
BUZ INVESTORS  Invictus MD announces $40,000,000 Bought Deal INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) announced today that it has engaged Canaccord Genuity Corp. and Eventus Capital Corp., as co-lead underwriters and joint-bookrunners, on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought deal private placement basis, subject to adjustment pursuant to the Underwriters’ Option (as hereinafter defined), $40 million aggregate principal amount of convertible debentures (the “Convertible Debentures”) at a price of $1,000 per Convertible Debenture (the “Offering”).Invictus MD has also granted the Underwriters an option (the “Underwriters’ Option”) to purchase up to an additional $10 million aggregate principal amount of convertible debentures on the same terms as the Convertible Debentures pursuant to the Offering (together with the Convertible Debentures, the “Debentures”). If the Underwriters’ Option is exercised in full, the aggregate gross proceeds of the Offering will be $50 million.




 Invictus MD announces $40,000,000 Bought Deal

The Debentures will bear interest from the date of closing at 8% per annum, payable semi-annually on June 30 and December 31 of each year. The Debentures will have a maturity date of 24 months from the Closing Date of the Offering (the “Maturity Date”).  Net proceeds from the Offering will be used primarily towards expansion and growth opportunities.

The Debentures will be convertible at the option of the holder into common shares of the Company (“Common Shares”) beginning on the date that is four months following the Closing Date and any time prior to the close of business on the Maturity Date at a conversion price of $2.00 per Common Share (the “Conversion Price”). Beginning on the date that is four months and one day following the Closing Date, the Company may force the conversion of all of the principal amount of the then outstanding Debentures at the Conversion Price on 30 days’ prior written notice should the daily volume weighted average trading price of the Common Shares be greater than $3.35, for any 10 consecutive trading days.

The Debentures will be subject to redemption, in whole or in part, by the Company at any time after 12 months upon giving Debenture holders not less than 30 and not more than 60 days’ prior written notice, at a price equal to the then outstanding principal amount of the Debentures plus all accrued and unpaid interest up to and including the redemption date. Upon a change of control of the Company, holders of the Debentures will have the right to require the Company to repurchase their Convertible Debentures, in whole or in part, on the date that is 30 days following the giving of notice of the change of control, at a price equal to 100% of the principal amount of the Debentures then outstanding plus accrued and unpaid interest thereon (the “Offer Price”). If 90% or more of the principal amount of the Debentures outstanding on the date of the notice of the change of control have been tendered for redemption, the Company will have the right to redeem all of the remaining Debentures at the Offer Price.

The Debentures and any Common Shares issuable upon conversion or exercise thereof, as applicable, will be subject to a statutory hold period lasting four months and one day following the closing date.

Closing of the Offering is expected to occur on or about May 9, 2017 (the “Closing Date”). The Offering is subject to certain conditions including, but not limited to, completion of the acquisition of Acreage Pharms, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange.

Notice of Intention to Exercise Option

The Company is also pleased to announce that further to its news release dated February 24, 2017, it has provided Acreage Pharms Ltd. (“Acreage Pharms”), a licensed producer of Cannabis under the Access to Cannabis for Medicinal Purposes Regulations (“ACMPR”), with notification that it intends to exercise its option to acquire 100% of Acreage Pharms’ shares from its current shareholders (the “Vendors”).

The consideration to be paid to the Vendors in connection with the exercise of the option is as follows: (i) a cash payment of $4 million; (ii) 21 million common shares; and (iii) 3 million warrants with an exercise price of $1.50 per warrant, of which: one third of the total number of warrants issued will expire every six months from the date of closing.

Canada is on the global stage for cannabis legalization and moves closer to making history by being the first G-7 nation to legalize and regulate access to cannabis for responsible adult consumption and we welcome the regulatory framework around legalization while reducing access for underage Canadians, keeping profits out of the hands of the black market, and ensuring that customers are protected by having access to clean and safe product. This is of utmost importance, given the expected demand that will come with cannabis legalization for the recreational market.

We embrace the role we will play in the establishment of a secure environment for the continued development of a new cannabis economy that will generate even greater investment, innovation, economic development and job creation to many locations across Canada.

As Canada embarks on this historic and brave path, Invictus MD looks forward to working alongside with all levels of government to achieve its goal of keeping cannabis out of the hands of youth and establishing a legitimate market while eradicating the black market.

The Offering is in the form of a bought deal private placement (i) in Canada to “accredited investors” within the meaning of National Instrument 45-106 and other exempt purchasers in each province of Canada, as agreed upon by the Issuer and the Underwriters, (ii) in the United States in accordance with exemption to the registration requirement under applicable United States securities law, and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the common shares, Warrants, Warrant Shares of the Issuer.

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR located in both Alberta and Ontario, including Acreage Pharms Ltd. and AB Laboratories Inc. and Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Featured Video Play Icon

Talga CEO on Chemetall Deal and Becoming a Commercialized Graphene Player

Talga CEO on Chemetall Deal and Becoming a Commercialized Graphene Player

 

BUZ INVESTORS Chemetall Deal  Mark Thompson, Managing Director of Talga Resources Ltd (ASX: TLG), in an interview with InvestorIntel’s CEO Tracy Weslosky discuss their joint development agreement (JDA) with Chemetall, part of BASF, and their new, “mega [cobalt] project.” The deal with Chemetall will commercialize graphene and will position them in the $10 billion a year metal protective treatments sector. Talga signed another JDA with Zinergy, a UK-based flexible battery company earlier this year. Moreover, they picked up pristine cobalt assets in Kiskama, Sweden in 2012. They confirmed the sensational results of historical drill cores and will have assaying results to appraise the entire property. Talga has another cobalt rich project to the southeast: the Lautakoski iron oxide copper gold (IOCG) deposit. Mark will explore the dynamic cleantech applications for the graphene market at the Cleantech and Technology Metals Summit on May 15 and 16.



OTHER STORIES BUZ TRADERS FOLLOW

Chemetall Deal

Tracy Weslosky: Allow me to start by congratulating you on your announcement with Chemetall. I understand your stock is moving rapidly on the news. Can you give us some highlights please?

Mark Thompson: Chemetall is a subsidiary of BASF, which is one of the world’s tier one global coatings and chemical giants. This is a very significant group to allow essentially us to go public with a relationship with them and what follows quite along, a sampling regime. We’re commercializing some products. We have a product development deal with them that seems to be the last building block in people’s minds about the commercial ability of graphene.

Tracy Weslosky: Let’s take that a step further. I actually read that you’re looking at having revenue by Q2 of this year. Is that correct, and can you tell us just a little bit more about that?

Mark Thompson: Even though it’s a sample development or I should say a product development agreement, Chemetall have agreed to buy the material from that program. This will provide income to Talga – obviously very small at first and then hopefully growing throughout the length of the agreement. Then there will be a separate discussion about commercializing that material, but still significant in that, it’s quite an evolution from just providing raw materials. This is actually more of a value added situation.

Tracy Weslosky: It is value added. Of course, this helps with corrosion. Can you give us an overview about how significant this graphene commercialization process is?

Mark Thompson: First of all, what we like about graphene and coatings is it has a massive improvement in performance. Particularly with anti-corrosion, graphene can outperform currently used materials, like chrome, that are used in these coatings now. The ultra-thin and impermeable nature of graphene, plus its electrical conductivity allows it to outperform a lot of other materials. You get a really big bang for your buck by putting graphene into your coating. You get a lot of leverage from that because you also need a very small amount of graphene in that coating


Ebates Coupons and Cash Back



Commodities ( Gold ) ( Silver ) ( Lithium )




Invictus MD Announces $15,015,000 Bought Deal Private Placement of Units

Invictus MD Closes $16,218,065 Bought Deal Private Placement

Invictus MD Closes $16,218,065 Bought Deal Private Placement

Invictus MD Closes $16,218,065 Bought Deal Private Placement

Invictus MD Closes Vancouver, BC / March 2, 2017 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has closed its previously announced bought deal private placement (the “Offering”), with Canaccord Genuity Corp. and Eventus Capital Corp. (collectively, the “Underwriters”), including a portion of the over-allotment option, for aggregate gross proceeds of $16,218,065. A total of 9,829,130 units (the “Units”), including those pursuant to the exercise of the over-allotment option, were issued at a price of $1.65 per Unit.

Each Unit is comprised of one common share and one half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share (a “Warrant Share”) until September 2, 2018 at an exercise price of $2.35 per Warrant Share. The Warrants are subject to an acceleration provision that allows the Company to give notice of an earlier expiry date if the Company’s daily volume weighted average share price on the Canadian Securities Exchange (or such other stock exchange the Company may be trading on) is greater than $3.75 for 10 consecutive trading days .



OTHER STORIES BUZ TRADERS FOLLOW

Invictus MD Closes

 

Net proceeds from the Offering will be used for expansion plans for the Company’s assets and for general working capital purposes. As compensation, the Underwriters received a commission of 7% of the gross proceeds raised which was paid partly in cash and partly through the issuance of 281,818 Units having the same terms as the Units issued to purchasers.   The Company also issued to the Underwriters a total of 688,039 Underwriters’ warrants.  Each Underwriters’ warrant is exercisable to acquire one common share at a price of $1.65 until September 2, 2018 .

All securities issued or issuable under the Offering are subject to a four-month hold period expiring on July 3, 2017.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )